| March
29, 2007--Roche
is paying about $155 million for 454 Life Sciences
Corporation, a majority-owned subsidiary of CuraGen
Corporation. Roche
reportedly plans to maintain the 454 Life Sciences
facility in Branford, Connecticut with its 167 employees
as a fully integrated part of the Roche Diagnostics
organization. CuraGen established 454 Life Sciences in
2000 to develop and commercialize next-generation
sequencing technology. In May 2005, 454 Life Sciences and
Roche signed a research and marketing collaboration making
Roche Diagnostics the exclusive worldwide distributor of
454’s Genome Sequencer systems and associated reagents
to all markets with the exception of regulated
diagnostics. By acquiring 454, Roche Diagnostics has
access to future sequencing products and can apply them in
regulated diagnostic applications.
For
more information see CuraGen
press release.
|
